meta
|
evidence
COVID-19
Living systematic review and meta-analysis
adjuvant therapies
anti-inflammatoty and immuno-therapy
Immunostimulants drugs
anti-PD-1 antibody
CD24Fc
convalescent plasma treatment
Deferred Convalescent plasma
Early convalescent plasma.
immunoglobulin therapy
inactivated mycobacterium vaccine
interferon
Interleukin-2
levamisole
neutralizing antibody
rhG-CSF
antiandrogenic
antiviral and associated therapy
control
Drugs for acid related disorders
miscellaneous
Oral antidiabetic drugs
Renin-angiotensin-system-acting agents
vaccines
Vitamins
potential COVID-19 treatments
anti-inflammatoty and immuno-therapy
Immunostimulants drugs
convalescent plasma treatment
control
placebo
standard of care
All
COVID 19 hospitalized
COVID 19 all comers
COVID-19 mild to moderate
COVID-19 severe or critically
COVID 19 outpatients
COVID-19 (hospitalized or not)
COVID-19 prophylaxis (children)
COVID-19 prophylaxis (excluding children)
infections other than COVID-19
Long COVID-19
preventing respiratory virus transmission
secondary prevention
patient subgroup...
age >= 55 yr
age >= 65 yr
critical disease
Studies
Mapping
Meta-analysis
Excluded
Study
Exclusion reasons
Remarks
Reference(s)
Empty list - no studies excluded